Staging of neuroblastoma includes examination of bone marrow trephine biopsy specimens for detection of bone marrow infiltration at diagnosis and residual tumour after chemotherapy. In (fig 3) . Only one of the three "cicatricial type" bone The three so-called "cicatricial-type" were cases studied after chemotherapy. These showed fibrotic foci probably corresponding to regressing metastases, but no neoplastic cells were shown by conventional histology. Immunostaining for NSE detected neoplastic cells in one of these bone marrows and so showed the persistence of tumour.
Immunostaining by the peroxidase antiperoxidase technique in bone marrow specimens requires the inhibition of endogenous peroxidase that is normally present in some granulocytic cells. This is easily accomplished with H202. Otherwise metastases may be falsely detected. Nevertheless, this might represent a problem of interpretation, as none of our bone marrow specimens showed reactivity in granulocytic cells or osteoblasts. False negativity after decalcification of tissues has been considered a limitation of immunoperoxidase methods. When immunoreactivity was compared in decalcified and non-decalcified tissues, however, there was no considerable difference in immunoreactivity.5 Only one of the bone marrows invaded by other tumours was positive for NSE. The case corresponded to Ewing's sarcoma of the tibia. The presence of NSE in some cases of Ewing's sarcoma is consistent with the findings of recent studies. 2 We conclude that immunostaining for NSE increases the rate of detection of bone marrow invasion by neuroblastoma cells. It detects very small aggregates of malignant cells. The prognostic value of these small metastases and particularly the mature ganglion cells (fig 3) , however, remains questionable.
Many other antibodies have been tested for diagnosis of neuroblastoma,6 but most of them are only useful in frozen sections or in cytology.
Moreover, their specificity has not been accurately determined. NSE is currently the most sensitive immunomarker for neuroectodermal tumours.7'
